As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Depression Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 224 high prescribing primary care physician and psychiatrists and detailed discussions with KOLs. Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed


US Japan France Germany Italy Spain UK
Primary care physicians 20 12 22 21 20 24 20
Psychiatrists 10 21 10 10 10 14 10

Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Dysthymia
  • Major depressive disorder
  • Treatment-resistant major depression
Drugs profiled
  • Abilify
  • Brintellix
  • Cymbalta
  • Effexor XR
  • Fetzima
  • Lexapro
  • Pristiq
  • Seroquel XR
  • Valdoxan
  • Viibryd
  • ALKS 5461
  • Vyvanse
  • Brexpiprazole
  • Edivoxetine



Key Findings

The ongoing strong growth of Cymbalta and Abilify for depression will be short-lived as both blockbusters are nearing loss of exclusivity. Their patent expiries will herald another cliff in the depression market, lasting from the end of 2013 to 2016.

The newly approved antidepressant Brintellix will help to restore the overall market to growth and attain approximately $900m in depression-specific sales across the US, Japan, and five major EU markets by 2021. Lundbeck and Takeda have compiled an impressive dataset to support Brintellix’s approvals, recently adding to it with evidence of superiority over Valdoxan in a head-to-head study.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726